TeamViewer Aktie 50049146 / DE000A2YN900
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | ||||||
|
21.10.2025 23:06:43
|
EQS-Adhoc: TeamViewer SE: TeamViewer discloses Q3 2025 results and updates FY 2025 pro forma guidance
|
EQS-Ad-hoc: TeamViewer SE / Key word(s): Change in Forecast Goeppingen, Germany, October 21, 2025 – In Q3 2025, and on a pro forma basis, TeamViewer delivered Revenue of € 192.0m (+4% cc yoy), reported Annual Recurring Revenue (ARR) of €756.8m (+4% cc yoy), and an Adj. EBITDA margin of 46 %. Based on this, and following a comprehensive review of the remaining deal pipeline for Q4 2025, management decided to update FY 2025 pro forma guidance as follows:
Management remains highly committed to accelerate ARR growth in 2026 and beyond. However, the reduced 2025 ARR expectations do impact 2026 Revenue: in a preliminary view, 2026 Revenue is expected to grow in a range of 2 – 6% yoy, i.e. to €790m – €825m (previously €850m – €870m).* All of the above is based on communicated guided FX rates.* TeamViewer will provide official FY 2026 guidance and further outlook for 2027 to 2029, including currency updates, with the publication of its Q4/FY 2025 results. On the occasion of today’s release, TeamViewer will pull forward the publication of its full set of Q3 and 9M 2025 results, which will be published immediately following this release.
Contact: Bisera Grubesic Vice President Investor Relations
* Based on assumptions on main FX rates as of Q4 2024: EUR/USD 1.05; EUR/CAD 1.49; EUR/JPY 161.0; EUR/AUD 1.65. End of Inside Information Information and Explanation of the Issuer to this announcement: Important notice Certain statements in this communication may constitute forward looking statements. These statements are based on assumptions that are believed to be reasonable at the time they are made, and are subject to significant risks and uncertainties, including, but not limited to, those risks and uncertainties described in TeamViewer’s disclosures. You should not rely on these forward-looking statements as predictions of future events, and TeamViewer’s actual results may differ materially and adversely from any forward-looking statements discussed in these statements due to several factors, including without limitation, risks from macroeconomic developments, external fraud, lack of innovation capabilities, inadequate data security and changes in competition levels. TeamViewer undertakes no obligation, and does not expect to publicly update, or publicly revise, any forward-looking statement, whether as a result of new information, future events or otherwise. All stated figures are unaudited. This document contains alternative performance measures (APM) that are not defined under IFRS, such as Annual Recurring Revenue (ARR) and Adjusted EBITDA. The APMs (non-IFRS) can be reconciled to the key performance indicators included in the IFRS consolidated financial statements and should not be viewed in isolation, but only as supplementary information for assessing the operating performance. TeamViewer believes that these APMs provide an additional, deeper understanding of the Company’s performance. Definitions of alternative performance measures (APMs) are included in the regular financial reporting of the company.
21-Oct-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | TeamViewer SE |
| Bahnhofsplatz 2 | |
| 73033 Göppingen | |
| Germany | |
| Phone: | +49 7161 60692 50 |
| Fax: | +49 7161 60692 335 |
| E-mail: | ir@teamviewer.com |
| Internet: | ir.teamviewer.com |
| ISIN: | DE000A2YN900 |
| WKN: | A2YN90 |
| Indices: | MDAX, TecDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2216474 |
| End of Announcement | EQS News Service |
|
|
2216474 21-Oct-2025 CET/CEST
Nachrichten zu TeamViewer
|
17:58 |
TecDAX aktuell: TecDAX zum Handelsende in Grün (finanzen.ch) | |
|
15:58 |
Starker Wochentag in Frankfurt: TecDAX verbucht Zuschläge (finanzen.ch) | |
|
12:26 |
Börse Frankfurt in Grün: TecDAX präsentiert sich am Mittag fester (finanzen.ch) | |
|
09:28 |
Handel in Frankfurt: TecDAX zeigt sich zum Start des Dienstagshandels fester (finanzen.ch) | |
|
10.11.25 |
Gewinne in Frankfurt: TecDAX legt schlussendlich zu (finanzen.ch) | |
|
10.11.25 |
EQS-PVR: TeamViewer SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group) | |
|
10.11.25 |
EQS-PVR: TeamViewer SE: Veröffentlichung gemäss § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung (EQS Group) | |
|
10.11.25 |
Pluszeichen in Frankfurt: TecDAX nachmittags freundlich (finanzen.ch) |
Analysen zu TeamViewer
| 05.11.25 | TeamViewer Neutral | Goldman Sachs Group Inc. | |
| 27.10.25 | TeamViewer Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 23.10.25 | TeamViewer Overweight | Barclays Capital | |
| 23.10.25 | TeamViewer Hold | Deutsche Bank AG | |
| 22.10.25 | TeamViewer Halten | DZ BANK |
Mittwoch um 18 Uhr live: Die Illusion der Erinnerung - Wie du Denkfehler im Trading vermeidest
Erfahrung ist wertvoll - doch Erinnerungen sind trügerisch. Sie verzerren, ergänzen oder lassen Details weg, bis ein falsches Bild entsteht. Dieses Webinar zeigt, warum das Gehirn keine objektive Aufzeichnung liefert und wie diese Verzerrungen Trading-Entscheidungen unbewusst beeinflussen.
Schnell noch Plätze sichern!Abnehmspritzen – Ist der Hype vorbei? – mit Tim Schäfer
Ist der Hype um Abnehmspritzen wie bei Novo Nordisk und Eli Lilly vorbei – oder stehen wir erst am Anfang einer langfristigen Revolution im Gesundheitswesen? 💉📉
Im heutigen Gespräch mit Tim Schäfer @TimSchaeferMedia sprechen wir über die spannendsten Pharmawerte 2025. Neben den Abnehmspritzen blicken wir auch auf klassische Pharma-Giganten wie Pfizer, Johnson & Johnson, Roche, Novartis, AstraZeneca und GSK. Tim analysiert Übertreibungen, Rücksetzer und langfristige Chancen für Buy-and-Hold-Strategien – mit Fokus auf Dividende, KGV und Krisenresistenz.
💬 Was ist vom Abnehmtrend langfristig zu halten?
💬 Welche Pharma-Aktien sind aktuell unterbewertet?
💬 Was spricht für konservative Dividendenwerte im Gesundheitssektor?
👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Aktien in diesem Artikel
| TeamViewer | 5.54 | -1.42% |
|
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
Warten auf anstehende Datenflut: Dow stark -- SMI letztlich fester -- DAX schliesslich freundlich -- Märkte in Fernost enden uneinheitlichSowohl der heimische als auch der deutsche Aktienmarkt präsentierten sich am Dienstag fester. Der US-Aktienmarkt bewegt sich am Dienstag in unterschiedliche Richtungen. Die wichtigsten asiatischen Börsen zeigten sich am Dienstag uneins.